- ￥990 - 3670
- Solarbio
- 北京
- IT3050
- 2025年10月10日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 保存条件：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 保质期：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 英文名：
Tecovirimat
- 库存：
现询
- 供应商：
北京索莱宝科技有限公司
- CAS号：
869572-92-9
- 规格：
10mg/5mg/1mg
| 规格： | 10mg | 产品价格： | ￥3670.0 |
|---|---|---|---|
| 规格： | 5mg | 产品价格： | ￥2290.0 |
| 规格： | 1mg | 产品价格： | ￥990.0 |
| 基本信息 | |
| CAS | No.869572-92-9 |
| 中文名称 | 特考韦瑞 |
| 英文名称 | Tecovirimat |
| 别名 | ST-246 |
| 分子式 | C19H15F3N2O3 |
| 分子量 | 376.33 |
| 溶解性 | Soluble in DMSO(Need ultrasonic) |
| 纯度 | ≥90% |
| 外观(性状) | Solid |
| 储存条件 | Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| SMILES | C1C2C1C3C=CC2C4C3C(=O)N(C4=O)NC(=O)C5=CC=C(C=C5)C(F)(F)F |
| InChIKey | CSKDFZIMJXRJGH-VWLPUNTISA-N |
| InChI | InChI=1S/C19H15F3N2O3/c20-19(21，22)9-3-1-8(2-4-9)16(25)23-24-17(26)14-10-5-6-11(13-7-12(10)13)15(14)18(24)27/h1-6，10-15H，7H2，(H，23，25)/t10-，11+，12+，13-，14-，15+ |
| PubChem CID | 16124688 |
| 靶点 | Antiviral |
| 通路 | Anti-infection |
| 背景说明 | 是一种Antiviral化合物，通过靶向病毒 p37 protein orthologs 来抑制正痘病毒orthopoxviruses的释放，可用于治疗Small-pox感染的相关研究。 |
| 生物活性 | Tecovirimat 是一种口服生物活性抗痘病毒化合物，对多种正痘病毒具有强效和选择性活性，EC50 约为 10 nM。[1-2] |
| In Vitro | Tecovirimat is potent(concentration that inhibited virus replication by 50% = 0.010 microM)，selective(concentration of compound that inhibited cell viability by 50% = >40 microM)，and active against multiple orthopoxviruses，including vaccinia，monkeypox，camelpox，cowpox，ectromelia(mousepox)，and variola viruses. In cell culture，tecovirimat inhibited plaque formation and virus-induced cytopathic effects. In single-cycle growth assays，tecovirimat reduced extracellular virus formation by 10 fold relative to untreated controls，while having little effect on the production of intracellular virus.[1] Tecovirimat against cowpox virus(CV)，vaccinia virus(VV)，and ectromelia virus(ECTV)and had an in vitro 50% effective concentration(EC50)of 0.48 microM against CV，0.05 microM against VV，and 0.07 microM against ECTV.[2] |
| 细胞实验 | In vivo oral administration of tecovirimat protected BALB/c mice from lethal infection，following intranasal inoculation with 10x 50% lethal dose(LD(50))of vaccinia virus strain IHD-J. Orally administered tecovirimat also protected A/NCr mice from lethal infection，following intranasal inoculation with 40，000x LD(50)of ectromelia virus. Oral administration of tecovirimat inhibited vaccinia virus-induced tail lesions in mice inoculated via the tail vein.[1] Tecovirimat(10-100mg/kg/d; 14-day; oral)administered to mice infected intranasally with CV significantly reduce mortality. Tecovirimat(100mg/kg/d; 5days)was administered to VV-infected mice significantly reduce mortality. Tecovirimat(10-100mg/kg/d; 10 days; oral)can prevent death in mice infected with ECTV.[2] |
| 数据来源文献 | [1]. Yang G，et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol. 2005 Oct;79(20):13139-49. [2]. Quenelle DC，et al. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother. 2007 Feb;51(2):689-95. |
| 单位 | 瓶 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
IT3050 特考韦瑞 抗感染 索莱宝
￥990 - 3670
